ALVO OAKTREE ACQUISITION CORP II

Granting of Stock Options and Vesting of Restricted Share Units

Granting of Stock Options and Vesting of Restricted Share Units

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.

The aim of the stock option grants is to align the long-term interests of the board members and the Company. The relevant key terms and conditions of the Company´s Equity Incentive Plan approved by Alvotech’s Annual and Extraordinary General Meeting on June 13, 2022 are as follows:

  • The stock option agreements entitle the grantee to purchase Alvotech shares at an exercise price of USD 9.28 per share*.
  • The options are subject to a vesting period over three years with yearly vesting, i.e. one third of the options vest each year starting on the AGM where the stock options were awarded.  
  • The options are only exercisable if the grantee is still a member of the board of Alvotech at the time of vesting.

Attached to this announcement are filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) made by the respective four independent board directors of their vested RSUs, in accordance with previous grants.

*The exercise price is determined by the opening price of the Company's ordinary shares on the Nasdaq US stock exchange on the date of the grant, in this case on June 25, 2025. 



Alvotech Investor Relations

Benedikt Stefansson, VP

Attachments



EN
01/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE

Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced a sale of 2,701,617 shares in Alvotech on January 30, 2026, and Aztiq Pharma Partners S.à r.l. ("Aztiq") announced the acquisition of 2,701,617 shares in Alvotech on January 30, 2026. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer of shares within the group. The announcements related to the same t...

 PRESS RELEASE

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila Í viðhengi eru tvær tilkynningar um viðskipti stjórnenda og tengdra aðila sem lagðar voru inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF). ATP Holdings ehf. tilkynnti um sölu á 2.701.617 bréfum þann 30. janúar sl. og Aztiq Pharma Partners S.à r.l. ("Aztiq") um kaup á 2.701.617 bréfum þann 30. janúar sl. ATP Holdings ehf. er í sömu samstæðu og Aztiq og var því um að ræða flutning bréfanna innan samstæðunnar. Tilkynningarnar vörðuðu sömu viðskipti og verð bréfanna í viðskiptunum var 4,...

 PRESS RELEASE

Alvotech Announces Increase in Number of Own Shares

Alvotech Announces Increase in Number of Own Shares REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. Th...

 PRESS RELEASE

Alvotech tilkynnir um aukningu í fjölda eigin bréfa

Alvotech tilkynnir um aukningu í fjölda eigin bréfa REYKJAVIK (11. febrúar 2026) - Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út tólf og hálfa milljón (12.500.000) nýrra almennra hluta í félaginu. Dótturfélag Alvotech, Alvotech Manco ehf. („dótturfélagið“) kaupir öll bréfin af móðurfélaginu á genginu 5,2 bandaríkjadalir á hlut. Hlutir dótturfélagsins eru taldir til eigin hlutabréfa Alvotech og fylgir þeim því hvorki atkvæðisréttur né réttur til arðgreiðslu. Að loknum þessum viðskiptum á dótturfélagið alls 16.254.005 hluti, eða um 4,7% útgefinna hl...

 PRESS RELEASE

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokine...

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT80, a bio...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch